Unknown

Dataset Information

0

Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival.


ABSTRACT: BACKGROUND:In the triple-negative breast cancer (TNBC) group, the luminal androgen receptor subtype is characterized by expression of androgen receptor (AR) and lack of estrogen receptor and cytokeratin 5/6 expression. Cathepsin D (Cath-D) is overproduced and hypersecreted by breast cancer (BC) cells and is a poor prognostic marker. We recently showed that in TNBC, Cath-D is a potential target for antibody-based therapy. This study evaluated the frequency of AR/Cath-D co-expression and its prognostic value in a large series of patients with non-metastatic TNBC. METHODS:AR and Cath-D expression was evaluated by immunohistochemistry in 147 non-metastatic TNBC. The threshold for AR positivity (AR+) was set at ?1% of stained cells, and the threshold for Cath-D positivity (Cath-D+) was moderate/strong staining intensity. Lymphocyte density, macrophage infiltration, PD-L1 and programmed cell death (PD-1) expression were assessed. RESULTS:Scarff-Bloom-Richardson grade 1-2 and lymph node invasion were more frequent, while macrophage infiltration was less frequent in AR+/Cath-D+ tumors (62.7%). In multivariate analyses, higher tumor size, no adjuvant chemotherapy and AR/Cath-D co-expression were independent prognostic factors of worse overall survival. CONCLUSIONS:AR/Cath-D co-expression independently predicted overall survival. Patients with TNBC in which AR and Cath-D are co-expressed could be eligible for combinatory therapy with androgen antagonists and anti-Cath-D human antibodies.

SUBMITTER: Mansouri H 

PROVIDER: S-EPMC7281089 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival.

Mansouri Hanane H   Alcaraz Lindsay B LB   Mollevi Caroline C   Mallavialle Aude A   Jacot William W   Boissière-Michot Florence F   Simony-Lafontaine Joelle J   Laurent-Matha Valérie V   Roger Pascal P   Liaudet-Coopman Emmanuelle E   Guiu Séverine S  

Cancers 20200515 5


<h4>Background</h4>In the triple-negative breast cancer (TNBC) group, the luminal androgen receptor subtype is characterized by expression of androgen receptor (AR) and lack of estrogen receptor and cytokeratin 5/6 expression. Cathepsin D (Cath-D) is overproduced and hypersecreted by breast cancer (BC) cells and is a poor prognostic marker. We recently showed that in TNBC, Cath-D is a potential target for antibody-based therapy. This study evaluated the frequency of AR/Cath-D co-expression and i  ...[more]

Similar Datasets

| S-EPMC5312352 | biostudies-literature
| S-EPMC8088339 | biostudies-literature
| S-EPMC5959383 | biostudies-literature
| S-EPMC8232227 | biostudies-literature
| S-EPMC9904386 | biostudies-literature
| S-EPMC4839343 | biostudies-literature
| S-EPMC6357448 | biostudies-literature
| S-EPMC5580391 | biostudies-literature
| S-EPMC6360707 | biostudies-literature